a. Daverport

46

PAGE: 1

RAW SEQUENCE LISTING PATENT APPLICATION US/08/496,847

1811 #y

DATE: 12/12/97

TIME: 16:10:26

INPUT SET: S22063.raw

This Raw Listing contains the General Information Section and up to the first 5 pages.

1		SEQUENCE LISTING General Information (i) APPLICANT: Amstutz, Gary A.
2		
3	(1)	General Information
4		// ADDITION TO A MARKATAN COMMAND
5		(i) APPLICANT: Amstutz, Gary A.
6		Bowersox, Stephen S.
7		Gohil, Kishorchandra
8		Adriaenssens, Peter I.
9		Kristipati, Ramasharma
10		(11) STEEL OF THE THURSDAY VERNIADO AND
11		(ii) TITLE OF THE INVENTION: METHODS AND
12		FORMULATIONS FOR PREVENTING PROGRESSION OF NEUROPATHIC PAIN
13		A LA LA MANAGER AND GRAVEWOOD AC
14		(iii) NUMBER OF SEQUENCES: 36
15		(to) GADDEGDANDENGE ADDDEGG
16		(iv) CORRESPONDENCE ADDRESS:
17		(A) ADDRESSEE: Dehlinger & Associates
18		(B) STREET: 350 Cambridge Avenue, Suite 250
19		(C) CITY: Palo Alto
20		(D) STATE: CA
21		(E) COUNTRY: US
22		(F) ZIP: 94306-1546
23 24		() CONDIMED DEADARE BODY.
24 25		(v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Diskette
25 26		· ·
26 27		(B) COMPUTER: IBM Compatible (C) OPERATING SYSTEM: DOS
28		(C) OPERATING SISTEM: BOS (D) SOFTWARE: FastSEQ for Windows Version 2.0
26 29		(D) SOFTWARE: FASCSEQ TOT WINDOWS VEISION 2.0
30		(vi) CURRENT APPLICATION DATA:
31		(A) APPLICATION NUMBER: 08/496,847
32		(A) APPLICATION NUMBER: 007498,047 (B) FILING DATE: 27-JUN-1995
33		(C) CLASSIFICATION:
34		(C) CLASSIFICATION:
35		(viii) ATTORNEY/AGENT INFORMATION:
36		(A) NAME: Stratford, Carol A
37		(B) REGISTRATION NUMBER: 34,444
38		(C) REFERENCE/DOCKET NUMBER: 5865-0009.31
39		(ix) TELECOMMUNICATION INFORMATION:
40		(A) TELEPHONE: 650-324-0880
41		(B) TELEFAX: 650-324-0860
42		(D) IBBERG: 030-324-0900
43		
44	(2)	INFORMATION FOR SEQ ID NO:1:
45	(2)	INFORMATION FOR DEG ID NO.1.
4 J		

(i) SEQUENCE CHARACTERISTICS:

99

RAW SEQUENCE LISTING PATENT APPLICATION US/08/496,847

INPUT SET: S22063.raw

DATE: 12/12/97 TIME: 16:10:31

		INPUT SET: S22063.
47		(A) LENGTH: 25 amino acids
48		(B) TYPE: amino acid
49		(D) TOPOLOGY: linear
50		(4)
51	(11)	MOLECULE TYPE: protein
52	(/	process
53	/iii\	HYPOTHETICAL: NO
54	(111)	mirothalican. No
55	(vi)	ORIGINAL SOURCE:
56	(\ \ 1)	
50 57		(C) INDIVIDUAL ISOLATE: MVIIA/SNX-111, FIGURE 1
		•
58	4 m 4 N	CHOURNON PROGRAMMON, CHO ID NO.1.
59	(X1)	SEQUENCE DESCRIPTION: SEQ ID NO:1:
60	~	
61	_	Lys Gly Lys Gly Ala Lys Cys Ser Arg Leu Met Tyr Asp Cys Cys
62	1	5 10 15
63		
64	Thr	Gly Ser Cys Arg Ser Gly Lys Cys
65		20 25
66		
67	(2) INFO	RMATION FOR SEQ ID NO:2:
68		
69	(i)	SEQUENCE CHARACTERISTICS:
70		(A) LENGTH: 25 amino acids
71		(B) TYPE: amino acid
72		(D) TOPOLOGY: linear
73		
74	(ii)	MOLECULE TYPE: protein
75		•
76	(iii)	HYPOTHETICAL: NO
77		
78	(Vi)	ORIGINAL SOURCE:
79		(C) INDIVIDUAL ISOLATE: MVIIB/SNX-159, FIGURE 1
80		
81		
82		
83	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:2:
84	` '	-
85	Cys	Lys Gly Lys Gly Ala Ser Cys His Arg Thr Ser Tyr Asp Cys Cys
86	1	5 10 15
87		
88	Thr	Gly Ser Cys Asn Arg Gly Lys Cys
89		20 25
90		
91	(2) INFO	RMATION FOR SEQ ID NO:3:
92	(2) 11120.	
93	(i)	SEQUENCE CHARACTERISTICS:
94	(-)	(A) LENGTH: 27 amino acids
95		(B) TYPE: amino acid
96		(D) TOPOLOGY: linear
97		(2) 1010001. IIII001
98	/441	MOLECULE TYPE: protein
70	(11)	MODECOLE TIPE: PLOCETH

RAW SEQUENCE LISTING PATENT APPLICATION US/08/496,847

DATE: 12/12/97 TIME: 16:10:36

INPUT SET: S22063.raw (iii) HYPOTHETICAL: NO 100 101 102 (vi) ORIGINAL SOURCE: 103 (C) INDIVIDUAL ISOLATE: GVÏA/SNX-124, FIGURE 1 104 105 (ix) FEATURE: (A) NAME/KEY: Modified-site 106 (B) LOCATION: 4 107 108 (D) OTHER INFORMATION: /note= "where X is hydroxyproline" 109 (ix) FEATURE: 110 111 (A) NAME/KEY: Modified-site 112 (B) LOCATION: 10 113 (D) OTHER INFORMATION: /note= "where X is hydroxyproline" 114 (ix) FEATURE: 115 (A) NAME/KEY: Modified-site 116 (B) LOCATION: 21 117 (D) OTHER INFORMATION: /note= "where X is hydroxyproline" 118 119 120 121 122 123 124 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: 125 126 127 Cys Lys Ser Xaa Gly Ser Ser Cys Ser Xaa Thr Ser Tyr Asn Cys Cys 128 129 Arg Ser Cys Asn Xaa Tyr Thr Lys Arg Cys Tyr 130 131 20 132 133 (2) INFORMATION FOR SEQ ID NO:4: 134 135 (i) SEQUENCE CHARACTERISTICS: 136 (A) LENGTH: 29 amino acids . 137 (B) TYPE: amino acid 138 (D) TOPOLOGY: linear 139 140 (ii) MOLECULE TYPE: protein 141 142 (iii) HYPOTHETICAL: NO 143 144 (vi) ORIGINAL SOURCE: 145 (C) INDIVIDUAL ISOLATE: GVIIA/SNX-178, FIGURE 1 146 (ix) FEATURE: 147 (A) NAME/KEY: Modified-site 148 149 (B) LOCATION: 4 (D) OTHER INFORMATION: /note= "where X is hydroxyproline" 150 151 152 (ix) FEATURE:

RAW SEQUENCE LISTING PATENT APPLICATION US/08/496,847

TIME: 16:10:42

DATE: 12/12/97

	INPUT SET:	S22063.raw
153		
154		
155	` '	ine"
156		
157		
158	• • • •	
159 160		e Cve
161	• • • • • • • • • • • • • • • • • • • •	_
162		
163		
164		
165		
166		
167	, -, -, -, -, -, -, -, -, -, -, -, -, -,	
168 169		
170	· · -	
171	· · ·	
172	· ·	
173		
174	` '	
175		
176 177	· ·	
178		
179		
180		
181	(ix) FEATURE:	
182	, ,	
183		n
184	• •	ıne"
185 186		
187		
188		
189	, ,	ine"
190		
191		
192	• • -	
193 194		e Cue
195		
196		
197		
198		
199		
200	• •	
201		
202 203	(i) SEQUENCE CHARACTERISTICS:	
20.7		
204	(A) LENGTH: 24 amino acids	

RAW SEQUENCE LISTING PATENT APPLICATION US/08/496,847

DATE: 12/12/97 TIME: 16:10:47

INPUT SET: S22063.raw

		INPUT SEI: S22063.
206		MOT DOUBLE THE CONTRACTOR OF T
207	(11)	MOLECULE TYPE: protein
208 209	,,,,,	HUDOMIEMTONI . NO
210	(111)	HYPOTHETICAL: NO
211	/*** \	ORIGINAL SOURCE:
211	(41)	(C) INDIVIDUAL ISOLATE: SVIA/SNX-157, FIGURE 1
212		(C) INDIVIDUAL ISOLATE: SVIA/SNA-15/, FIGURE I
214	/ig\	FEATURE:
215	(IX)	(A) NAME/KEY: Modified-site
216		(B) LOCATION: 7
217		(D) OTHER INFORMATION: /note= "where X is hydroxyproline"
218		(b) office the distribution / note - whole it is injurity profile
219		
220	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:6:
221	(/	
222	Cvs	Arg Ser Ser Gly Ser Xaa Cys Gly Val Thr Ser Ile Cys Cys Gly
223	. 1	5 10 15
224		
225	Arg	Cys Tyr Arg Gly Lys Cys Thr
226	J	20
227		
228	(2) INFO	RMATION FOR SEQ ID NO:7:
229		
230	(i)	SEQUENCE CHARACTERISTICS:
231		(A) LENGTH: 27 amino acids
232		(B) TYPE: amino acid
233		(D) TOPOLOGY: linear
234		
235	(ii)	MOLECULE TYPE: protein
236		
237	(111)	HYPOTHETICAL: NO
238		ADTATULE GAUDAD
239	(V1)	ORIGINAL SOURCE:
240 241		(C) INDIVIDUAL ISOLATE: TVIA/SNX-185, FIGURE 1
241	(+ + +)	FEATURE:
242	(IX)	(A) NAME/KEY: Modified-site
243		(B) LOCATION: 4
245		(D) OTHER INFORMATION: /note= "where X is hydroxyproline"
246		(b) office information. / note- where a is hydroxyproffice
247	(ix)	FEATURE:
248	(11)	(A) NAME/KEY: Modified-site
249		(B) LOCATION: 10
250		(D) OTHER INFORMATION: /note= "where X is hydroxyproline"
251		(-,
252	(ix)	FEATURE:
253	(= /	(A) NAME/KEY: Modified-site
254		(B) LOCATION: 21
255		(D) OTHER INFORMATION: /note= "where X is hydroxyproline"
256		
257		
258	(xi)	SEQUENCE DESCRIPTION: SEQ ID NO:7:

SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/08/496,847

DATE: 12/12/97 TIME: 16:10:52

INPUT SET: S22063.raw

Line Error

Original Text